# Ruijian Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruijian-biotech

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Angel (Jul 19, 2022)
- Investors on record: 1

## About

Based in Shenzhen, China, and founded in 2019, Ruijian Biotech is a developer of psychotropic drugs. As of 2022, it completed a round of financing. The company's founder used to be an assistant professor in the Department of Psychiatry of the University of Toronto, Canada. The co-founder graduated from Capital Medical University.

The company has three technology platforms, including protein-protein interaction analysis platforms, cell-penetrating peptide/PDC platforms, and high throughput screening platforms for neuro medicines. The company's pipelines include resistant depression, antidrug addiction, and PTSD. Its first pipeline is a non-opioid powerful analgesic that can penetrate the blood-brain barrier, which will enhance drug effectiveness, convenience, and accessibility.

## Funding rounds

- Angel, Jul 19, 2022 — Goldport Capital

## Investors

- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Angel